文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT预测局部晚期食管鳞癌患者新辅助PD-L1阻断单药治疗反应:一项初步研究

[18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-01-02

在单臂1b期NATION-1907试验中,23例局部晚期食管鳞癌患者接受两周期新辅助PD-L1阻断剂Adebrelimab后手术,其中18例在免疫治疗前和术前均行18F-FDG PET/CT。原发灶分析中,10例为良好反应者、8例为不良反应者;淋巴结分析中,7枚为良好反应者、10枚为不良反应者。代谢参数尤其是%ΔMTV和%ΔTLG可有效预测原发灶和淋巴结的良好反应者。

要点

  • 原发灶%ΔMTV41预测良好反应者的AUC为0.875,cut-off为-31.01。
  • 淋巴结%ΔTLG50预测良好反应者的AUC为1.000,cut-off为-7.5。
  • 原发灶与淋巴结的代谢反应评估之间无显著相关性。

核心结论

  • 18F-FDG PET/CT代谢参数,尤其是%ΔMTV和%ΔTLG,可有效预测局部晚期食管鳞癌原发灶和淋巴结对新辅助PD-L1阻断单药治疗的良好反应者。
  • 该结果可能有助于个体化免疫治疗,并可作为未来更大规模研究的分层工具。

研究设计与样本

  • 单臂1b期NATION-1907试验(NCT04215471),23例局部晚期食管鳞癌患者接受两周期新辅助PD-L1阻断剂Adebrelimab后手术,其中18例在免疫治疗前和术前均行18F-FDG PET/CT。

主要发现

  • 原发灶分析中,10例为良好反应者、8例为不良反应者;除MTV外,良好反应者治疗后所有代谢参数均显著低于不良反应者。
  • 不良反应者组%ΔMTV和%ΔTLG显著更高(均P<0.05)。
  • ROC曲线显示%ΔMTV41预测良好反应者性能最佳,AUC为0.875(cut-off:-31.01);%ΔMTV41显著预测无复发生存(P<0.1)。
  • 淋巴结分析中,7枚为良好反应者、10枚为不良反应者;不良反应者治疗前SULmax和SULpeak显著低于良好反应者。
  • 不良反应者组治疗后MTV50及所有参数百分比变化显著更高(均P<0.05);%ΔTLG50预测良好反应者AUC为1.000(cut-off:-7.5);原发灶与淋巴结代谢反应评估间无显著相关性。

关键数值与推荐

  • 残留存活肿瘤≤33%定义为良好反应者,>33%定义为不良反应者。
  • 病灶>1cm³分别以SULmax的41%和50%为阈值分割,按EANM指南计算MTV和TLG。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为初步研究(preliminary study)。
  • 原文结论提出该结果可能有助于个体化免疫治疗,并可作为未来更大规模研究的分层工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([18F]FDG) PET/CT for evaluating primary tumor (PT) and lymph node (LN) responses after neoadjuvant programmed death-ligand 1 (PD-L1) blockade monotherapy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC). METHODS: In the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [18F]FDG PET/CT scans both before immunotherapy and prior to surgery. Standardized uptake value corrected for lean body mass (SUL)-derived parameters, including SULmax and SULpeak, were documented for PTs and LNs. Lesions > 1cm3 were segmented using thresholds of 41% and 50% of SULmax, respectively, following European Association of Nuclear Medicine (EANM) guidelines, with metabolic tumor volume (MTV) and total lesion glycolysis (TLG) calculated. Percentage changes of all metabolic parameters were also recorded. Residual viable tumor ≤ 33% were classified as well-responders, whereas residual viable tumor > 33% were classified as poor-responders based on histological evaluation. RESULTS: In the PT analysis, 10 patients were classified as PT well-responders and 8 as PT poor-responders. All post-treatment metabolic parameters, except MTV, were significantly lower in well-responders compared to poor-responders. The %ΔMTV, %ΔTLG were significantly higher in the poor-responder group (all P < 0.05). ROC curves indicated %ΔMTV41 exhibited optimum performance in predicting well-responders, with an AUC of 0.875 (cut-off: -31.01). Furthermore, %ΔMTV41 significantly predicted patients' recurrence-free survival (RFS) (P < 0.1). In the LN analysis, 7 LNs were classified as well-responders and 10 as poor-responders. Pre-treatment SULmax, SULpeak were significantly lower in poor-responders compared to well-responders. Post-treatment MTV50 and all percentage changes in parameters were significantly higher in the poor-responder group (all P < 0.05). Receiver operating characteristic curve (ROC) analysis indicated %ΔTLG50 had excellent predictive performance for well-responders, with an AUC of 1.000 (cut-off: -7.5). However, there was no significant correlation between the metabolic response evaluations for PTs and LNs. CONCLUSION: The metabolic parameters of [18F]FDG PET/CT, particularly %ΔMTV and %ΔTLG, could effectively predict well-responders among both PTs and LNs to neoadjuvant PD-L1 blockade monotherapy in LA-ESCC, which may facilitate personalized immunotherapy and serve as a stratification tool in future larger-scale studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yang R, Tang H, Xie Y, et al. [18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study. Eur J Nucl Med Mol Imaging. 2025. PMID: 39743618. doi:10.1007/s00259-024-07051-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。